Key result
Patent arteriovenous fistulas did not significantly affect cardiovascular abnormalities such as left ventricular hypertrophy and left ventricular mass index in renal transplant recipients.
Why the study?
Does a patent arteriovenous fistula contribute to persistent left ventricular hypertrophy in renal allograft recipients?
Observational (n=130)
Does a patent arteriovenous fistula contribute to persistent left ventricular hypertrophy in renal allograft recipients?
Patent arteriovenous fistulas do not appear to contribute to persistent left ventricular hypertrophy or other cardiovascular abnormalities in renal transplant recipients.
No takes yet. Share an insight, caveat, or question.
Patent AVF does not worsen post-transplant LVH or LVMI; leaves open selective closure benefit in high-flow cases.
Görgülü et al. (2011) conducted an observational in Renal allograft recipients (n=130). Patent arteriovenous fistula vs. Closed AVF or no history of AVF was evaluated on Clinical, laboratory, and echocardiographic findings including LVH and LV mass index. Patent arteriovenous fistulas did not significantly affect cardiovascular abnormalities such as left ventricular hypertrophy and left ventricular mass index in renal transplant recipients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: